The Biggest R&D Spenders in Biopharma 2011(0)

Last year, pharma did better on the development front, seeing a modest increase in new drug approvals, which helped inspire talk of a turnaround. But long after all the economizing and efficiency reviews have been launched, R&D expenses continue to go up. This past year, the top 10 collectively registered expenses of a bit more than $70 billion, up slightly over the year before, according to the figures we collected.

• Novartis -
• 2011 spending: $9.58 billion
  2010 spending: $9.0 billion
  Change: +6.4%
  Percentage of revenue: 16.3%
  
  

• Pfizer -
• 2011 spending: $9.1 billion
  2010 spending: $9.4 billion
  Change: -3%
  Percentage of revenue: 13.5%

• Roche -
• 2011 spending: $8.8 billion
  2010 spending: $9.2 billion
  Change: -4.3%
  Percentage of revenue: 19%
  
  

• Merck -
• 2011 spending: $8.4 billion
  2010 spending: $8.12 billion
  Change: +3.4%
  Percentage of revenue: 17.5%
  
  

• Johnson & Johnson -
• 2011 spending: $7.5 billion
  2010 spending: $6.8 billion
  Change: +10%
  Percentage of revenue: 11.5%
  
  

• GlaxoSmithKline -
• 2011 spending: $6.29 billion
  2010 spending: $6.37 billion
  Change: -1.4%
  Percentage of revenue: 14.2%

• Sanofi -
• 2011 spending: $6.24 billion
  2010 spending: $5.9 billion
  Change: +5%
  Percentage of revenue: 13.5%

• AstraZeneca -
• 2011 spending: $5.5 billion
  2010 spending: $5.3 billion
  Change: +3.6%
  Percentage of revenue: 16.3%

• Eli Lilly -
• 2011 spending: $5 billion
  2010 spending: $4.88 billion
  Change: +3%
  Percentage of revenue: 20.6%

• Bristol-Myers Squibb -
• 2011 spending: $3.8 billion
  2010 spending: $3.56 billion
  Change: + 6.7%
  Percentage of revenue: 17.9%
  
  

Ver